Successful treatment of resistant pseudogout with anakinra.
We describe herein the case of a 63-year-old man with pseudogout affecting multiple joints that was resistant to treatment with allopurinol, steroids, and antiinflammatory drugs. Based on recent data on the molecular mechanism of pseudogout that demonstrated overproduction of interleukin-1 (IL-1), we treated the patient with anakinra, an IL-1 receptor antagonist. The patient responded to treatment with anakinra within 2 weeks, with resolution of the signs and symptoms of pseudogout and normalization of levels of inflammation markers.
McGonagle
Dennis
D
Calderdale Royal Hospital, Halifax, UK. d.g.mcgonagle@leeds.ac.uk
Tan
Ai Lyn
AL
Madden
Julie
J
Emery
Paul
P
McDermott
Michael F
MF
D018501:Antirheumatic Agents / Q000008:administration & dosage*; D015415:Biomarkers; D002805:Chondrocalcinosis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D005260:Female; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein / Q000008:administration & dosage*; D008875:Middle Aged
D018501:Antirheumatic Agents; D015415:Biomarkers; D053590:Interleukin 1 Receptor Antagonist Protein